SUZUKEN CO.,LTD. (9987) Stock Price

Suzuken operates a diverse range of businesses centered on pharmaceutical wholesale distribution. In the pharmaceutical wholesale business, Suzuken, along with subsidiaries including Sanki, Astis, Shoyaku, Suzuken Okinawa Yakuhin, Nakano Yakuhin, Suzuken Iwate, and S.D. Logi, distribute prescription pharmaceuticals, diagnostic reagents, and medical devices and supplies.

In the healthcare product development business, Sanwa Chemical Research Institute handles the manufacturing of prescription pharmaceuticals, while Kentz Medico manufactures medical devices and supplies. This enables the company to manage the entire value chain from research and development through manufacturing to sales of prescription pharmaceuticals, diagnostic reagents, and medical devices and supplies.

In the regional healthcare and long-term care support business, Unismile operates pharmacy services, while Sanki Wellbee and S-Care Mate provide long-term care services. Additionally, Medicare Collabo provides healthcare and long-term care support, delivering community-focused medical and care services.

In the specialty pharmaceutical distribution outsourcing business, S.D. Collabo provides manufacturer support services for specialty pharmaceuticals, efficiently supporting the distribution of specific pharmaceutical products.

In the medical-related services business, Chuo Transport and S.D. Collabo handle third-party logistics and undertake pharmaceutical manufacturer logistics outsourcing. Additionally, Collabo Place (to be renamed Collabo Square effective April 1, 2025) provides other services, including digital healthcare services.

Suzuken operates in the "health creation" business domain and is committed to contributing to society through healthcare and health-related fields. The company positions its relationships of trust with medical institutions, pharmacies, and pharmaceutical manufacturers as "traditional assets," and aims to continuously create new value that addresses social challenges and reduces societal costs.

Suzuken is implementing its medium-term management plan "For your next heartbeat ～Creating momentum toward the future～" from 2024 to 2026. This plan focuses on three priority areas: establishing service packages to protect the health of local residents, building efficient distribution functions that reduce pharmaceutical waste, and developing creative leadership talent.

Suzuken's medium-term management plan centers on two themes: "transforming existing operations" and "preparing new growth businesses." In transforming existing operations, the company will enhance productivity through healthcare distribution reform and strengthen profit structure. In preparing new growth businesses, the company aims to create new value by leveraging open innovation.

Suzuken is working to establish a sustainable social infrastructure foundation by advancing healthcare distribution reform and restructuring its Asian operations. To create a new healthcare ecosystem in Japan, the company is promoting smart logistics, digital healthcare, regional medical and care support, and healthcare product development.

To realize management that is conscious of capital costs and stock price, Suzuken aims to improve ROE. Specifically, the company is implementing balance sheet reforms that include reducing policy-held shares, strengthening shareholder returns, and utilizing appropriate debt levels, with the goal of achieving a PBR exceeding 1.0 in the near term.